Article
Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties.
Oncogene - 17 Nov 2016
Paranjape A N, Soundararajan R, Werden S J, Joseph R, Taube J H, Liu H, Rodriguez-Canales J, Sphyris N, Wistuba I, Miura N, Dhillon J, Mahajan N, Mahajan K, Chang J T, Ittmann M, Maity S N, Logothetis C, Tang D G, Mani S A
Abstract excerpt
Advanced prostate adenocarcinomas enriched in stem-cell features, as well as variant androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are difficult to treat, and account for up to 30% of prostate cancer-related deaths every year. While existing therapies for prostate cancer such as androgen deprivation therapy (ADT), destroy the bulk of the AR-positive cells within the tumor,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.